Management of Small Pleural Nodules with Anterior Uveitis and Positive TB Gold Test
This patient requires immediate initiation of standard anti-tuberculosis therapy (ATT) with rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 4 months (total 6 months), combined with systemic corticosteroids for the uveitis after ATT is started. 1
Diagnostic Confirmation
First, confirm this represents active tuberculosis disease rather than latent infection:
- Pleural nodules with positive TB Gold = presumed active TB until proven otherwise, especially with concurrent uveitis 2
- Obtain sputum samples (3 specimens, 8-24 hours apart, at least one early morning) for AFB smear and culture 3
- Consider pleural fluid analysis if effusion present - send 5-10 mL in blood culture bottles for highest yield 4
- Chest imaging to assess extent of disease 3
- Do NOT delay treatment while awaiting culture results - the combination of pleural nodules and uveitis with positive TB Gold warrants immediate empiric therapy 5
Treatment Algorithm
Anti-Tuberculosis Therapy (Primary Treatment)
Standard 6-month regimen 1:
- Initial phase (2 months): Rifampicin + Isoniazid + Pyrazinamide + Ethambutol daily
- Continuation phase (4 months): Rifampicin + Isoniazid daily
Dosing:
- Rifampicin: 600 mg daily (>50 kg) or 450 mg daily (<50 kg)
- Isoniazid: 300 mg daily
- Pyrazinamide: 2.0 g daily (>50 kg) or 1.5 g daily (<50 kg)
- Ethambutol: 15 mg/kg daily 1
Corticosteroid Management for Uveitis
Critical timing: Start corticosteroids ONLY after ATT is initiated 5, 6
- Begin with prednisolone 60-70 mg/day (or equivalent) 6
- Taper to maintenance dose of approximately 8-10 mg/day over 3 months 6
- Monitor for paradoxical worsening during first 2-3 months of ATT 7
Monitoring Requirements
Baseline assessments 1:
- Liver function tests (AST/ALT, bilirubin)
- Renal function (before ethambutol use)
- Visual acuity and color vision testing (ethambutol toxicity monitoring)
- Ophthalmologic examination with OCT and fluorescein angiography 8
During treatment:
- Liver function: If AST/ALT >2x normal at baseline, monitor weekly for 2 weeks, then biweekly 1
- Stop all drugs if AST/ALT rises to 5x normal or bilirubin rises 1
- Ophthalmologic follow-up: Monthly initially, then every 3 months 8
- Uveitis activity: Goal is zero anterior chamber cells 8
Critical Pitfalls to Avoid
Never use ethambutol without warning about visual symptoms - instruct patient to report vision changes immediately and stop drug 1
Do not use corticosteroids alone or before ATT - this can activate latent TB and worsen disease 5, 6
Avoid TNF-alpha blockers without isoniazid prophylaxis - if immunosuppression beyond corticosteroids is needed for refractory uveitis, use methotrexate first 8, 6
Do not stop treatment early - even if uveitis resolves quickly, complete the full 6-month ATT course 9. Studies show >9 months ATT reduces recurrence risk 11-fold compared to shorter courses 9
Watch for hepatotoxicity - inform patient to report fever, malaise, vomiting, or jaundice immediately 1
If Uveitis Remains Active Despite Treatment
After 3 months of ATT with adequate corticosteroids 8:
- First-line: Add methotrexate 8
- Second-line: Consider adalimumab (NOT etanercept, which is ineffective for TB-associated uveitis) 8
- Ensure isoniazid prophylaxis continues if using TNF-alpha blockers 6
Duration and Follow-up
- ATT duration: 6 months for pleural TB 1
- Corticosteroid taper: Over 3-6 months based on uveitis response 6
- Uveitis monitoring: Continue for 2 years after achieving inactive disease off topical steroids before considering stopping systemic immunosuppression 8
- Recurrence risk: Highest in first 6-12 months after completing ATT 10
This approach prioritizes preventing both TB progression (which affects mortality) and vision loss from uveitis (which affects quality of life), while minimizing treatment-related morbidity through careful monitoring.